Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complement Component 5a Receptor 1 (C5aR1), also known as CD88, is a G protein-coupled receptor (GPCR) that binds the complement component C5a. It is expressed on various immune cells and mediates inflammatory responses by promoting chemotaxis, cytokine secretion, and other immune functions. Dysregulation of C5aR1 contributes to several diseases, making it a therapeutic target for autoimmune diseases, sepsis, and cancer.
Agonists and antagonists modulate inflammatory responses through binding to C5aR1, affecting downstream signaling pathways like Gαi coupling, β-arrestin recruitment, and ERK/CAMK/Rho activation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complement Component 5a Receptor 1 (C5aR1).